Heterocyclic NMDA antagonists
A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.
1. A compound which is (4S)-3-{[2-(4-chloro-2-fluorophenoxy)pyrimidin-5-yl]methyl}-4-methyl-1,3-oxazolidine-2-one, or a salt thereof.
2. The compound according to claim 1 , which is crystalline (4S)-3-{[2-(4-chloro-2-fluorophenoxy)pyrimidin-5-yl]methyl}-4-methyl-1,3-oxazolidine-2-one characterized by a powder X-ray diffraction pattern comprising peaks at 5.4°±0.2°, 14.0°±0.2°, 16.3°±0.2°, 17.4°±0.2°, 18.6°±0.2°, 20.3°±0.2°, 21.0°±0.2°, 21.8°±0.2°, and 24.5°±0.2° degrees two theta.
3. The compound according to claim 1 , which is crystalline (4S)-3-{[2-(4-chloro-2-fluorophenoxy)pyrimidin-5-yl]methyl}-4-methyl-1,3-oxazolidine-2-one characterized by a powder X-ray diffraction pattern comprising at least three peaks at at least chosen from peaks at 5.4°±0.2°, 14.0°±0.2°, 16.3°±0.2°, 17.4°±0.2°, 18.6°±0.2°, 20.3°±0.2°, 21.0°±0.2°, 21.8°±0.2°, and 24.5°±0.2° degrees two theta.
4. The compound according to claim 1 , which is crystalline (4S)-3-{[2-(4-chloro-2-fluorophenoxy)pyrimidin-5-yl]methyl}-4-methyl-1,3-oxazolidine-2-one characterized by a powder X-ray diffraction pattern comprising at least four peaks chosen from peaks at 5.4°±0.2°, 14.0°±0.2°, 16.3°±0.2°, 17.4°±0.2°, 18.6°±0.2°, 20.3°±0.2°, 21.0°±0.2°, 21.8°±0.2°, and 24.5°±0.2° degrees two theta.
5. A pharmaceutical composition comprising (4S)-3-{[2-(4-chloro-2-fluorophenoxy)pyrimidin-5-yl]methyl}-4-methyl-1,3-oxazolidine-2-one or a salt thereof and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising crystalline (4S)-3-{[2-(4-chloro-2-fluorophenoxy)pyrimidin-5-yl]methyl}-4-methyl-1,3-oxazolidine-2-one characterized by a powder X-ray diffraction pattern comprising peaks at 5.4°±0.2°, 14.0°±0.2°, 16.3°±0.2°, 17.4°±0.2°, 18.6°±0.2°, 20.3°±0.2°, 21.0°±0.2°, 21.8°±0.2°, and 24.5°±0.2° degrees two theta and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition according to claim 5 , the pharmaceutical composition comprising crystalline (4S)-3-{[2-(4-chloro-2-fluorophenoxy)pyrimidin-5-yl]methyl}-4-methyl-1,3-oxazolidine-2-one characterized by a powder X-ray diffraction pattern comprising at least three peaks chosen from peaks at 5.4°±0.2°, 14.0°±0.2°, 16.3°±0.2°, 17.4°±0.2°, 18.6°±0.2°, 20.3°±0.2°, 21.0°±0.2°, 21.8°±0.2°, and 24.5°±0.2° degrees two theta and a pharmaceutically acceptable carrier.
8. The pharmaceutical composition according to claim 5 , the pharmaceutical composition comprising crystalline (4S)-3-{[2-(4-chloro-2-fluorophenoxy)pyrimidin-5-yl]methyl}-4-methyl-1,3-oxazolidine-2-one characterized by a powder X-ray diffraction pattern comprising at least four peaks chosen from peaks at 5.4°±0.2°, 14.0°±0.2°, 16.3°±0.2°, 17.4°±0.2°, 18.6°±0.2°, 20.3°±0.2°, 21.0°±0.2°, 21.8°±0.2°, and 24.5°±0.2° degrees two theta and a pharmaceutically acceptable carrier.